Journals / Çocuk Sağlığı ve Hastalıkları Dergisi / 1998 / Cilt: 41 - Sayı: 3

Evaluation of newborn patients with patent ductus arteriosus and indomethacin treatment

Yenidoğan bebeklerde patent duktus arteriozus ve indometazin tedavisinin değerlendirilmesi

Pages
327–333
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that of indomethacin therapy is important for treatment of patients with PDA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, 34 babies with symptomatic patent ductus arteriosus (PDA) were evaluated and followed up in the neonatal intensive care unit between 1994-1996.
📊
Key Findings & Data:The association of other cardiac defects with PDA was seen in eight (23.5%) cases.
💡
Conclusion & Impact:We conclude that of indomethacin therapy is important for treatment of patients with PDA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, 34 babies with symptomatic patent ductus arteriosus (PDA) were evaluated and followed up in the neonatal intensive care unit between 1994-1996. The association of other cardiac defects with PDA was seen in eight (23.5%) cases. PDA was diagnosed postnatally between the 2nd and 36th days (mean 9.0±6.7). Indomethacin treatment was given (1-12 doses, mean 3.4±1.9) to 26 babies (76.5%) between the 3rd and 15th days (mean 7.8±3.6). Ductus arteriosus closed in 21 cases (80.8%) after indomethacin treatment. Adverse effects were not seen in any cases. We conclude that of indomethacin therapy is important for treatment of patients with PDA.

Özet

Yenidoğan Yoğun Bakım Ünitesi'nde 1994-1996 yılları arasında semptomatik duktus arteriozus açıklığı tanısı konulan 34 vaka retrospektif olarak değerlendirildi. Dokuzunda (% 23.5) duktus açıklığı dışında kardiak anomali saptandı. Duktus açıklığı tanısı, postnatal 9.0±6.7 (2-36) günlerde konuldu. Endikasyonu olan 26 (% 76.5) bebeğe, 7.8±3.6 (3-15) günlerde, 3.4±1.9 (1-12) doz (0.2 mg/kg) indometazin intravenöz veya enterai yoldan uygulandı. İndometazin tedavisi ile 21 (% 80.8) vakanın duktusu 1.6±0.5) (0.5-3) günde kapandı ve yan etki gözlenmedi. İndometazinin duktus arteriozus açıklığı tedavisinde önemi tartışıldı.

🔖

Cite This Article

SATAR, M., NARLI, N., ATICI, A., ÖZBARLAS, N., KÜÇÜKOSMANOĞLU, O. (2022). Evaluation of newborn patients with patent ductus arteriosus and indomethacin treatment. Çocuk Sağlığı ve Hastalıkları Dergisi, Cilt: 41 - Sayı: 3, 327–333. https://ajindex.com/articles/649529